Major R&D Pipeline: 3ADCs
ENHERTU®: Revenue
(Bn JPY)
<Reference>
FY2021 Q1 Results
FY2021 Forecast
YOY
(as of Jul.)
vs. as of Apr.
Total
Consideration
Product Sales
Japan
US
Europe
ASCA
13.0
7.7
61.0
-8.4
2.2
2.0
13.4
9.6
4.6
42.4
-8.0
1.2
1.2
5.1
-0.4
0.2
Upfront payment
* 1
2.5
* 1
9.8
149.0
* 1
*1
Regulatory milestone payment
0.6
0.3
2.2
-2.6
33.7
US HER2+ Breast Cancer 3L
0.2
0.9
13.7
EU HER2+ Breast Cancer 3L
0.1
0.1
0.5
7.9
US HER2+ Gastric Cancer 2L + 3L
0.2
0.2
0.8
12.1
*2
US HER2+ or HER2 Mutant NSCLC 2L
-2.6
Total
16.0
8.1
73.1
-11.0
182.7
*1 Revenue recognized in each period
Daiichi-Sankyo
*2 Revenue based on the assumption that milestone will be achieved in FY2021; Expected consideration converted with forex rate of 105 JPY to 1 USD: 13.1 billion yen
11View entire presentation